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Reply to the Editor:
The comments by Dr. Goto were difficult for us to
understand. He noted that there was mild-to-moderate
calcification of glutaraldehyde-treated porcine aortic
cusps implanted in the pulmonary circulation of dogs,
whereas no calcific changes were observed in glutaralde-
hyde-treated valved conduits in the systemic circulation of
dogs. However, he provides no detailed explanation of
what this means. He also noted that the dog is not
generally considered to be a useful model for the study of
accelerated calcification. This sentence was quoted di-
rectly from the original article of Dr. Shemin.1 The point
of our article was the evaluation of a trileaflet biopros-
thetic valve both hemodynamically and pathologically.
Goto’s comments on this matter are also quoted in other
articles, as follows2, 3: The point of Dr. Shemin’s article
was the evaluation of a unileaflet pericardial bioprosthetic
valve both hemodynamically and pathologically in sheep
and was not for evaluation of calcification in the dog. Dr.
Shemin considered that the dog was not a useful model
for calcification according to previous investigations2, 3
that demonstrated no significant calcification despite 2
years of valve function in dogs.
We used dogs to evaluate our new conduit hemodynam-
ically and pathologically. The aim of our study was not the
evaluation of calcification. If Dr. Goto is interested in the
anticalcification effect of our bioprosthesis, we suggest he
may want to study our conduit in sheep. The details of the
graft processing are noted in “Materials and methods”
and “Discussion” of our article. References4, 5 are added
for additional clarification.
Dr. Goto explained the calcification of the polyepoxy
compound–treated aorta based on his colleague’s per-
sonal data. However, since this is not published informa-
tion, we would need more information to respond more
specifically. The laboratory data, including the number of
animals, name and concentration of the polyepoxy com-
pound, and the catalyst, reaction velocity, reaction time,
temperature, change of the pH during cross-linking, col-
lagen content of the aortic wall, cross-linking ratio of the
collagen, and the pK of the material in wet condition
would be necessary before we could comment.
Yukio Ichikawa, MD, PhD
Yasuharu Noishiki, MD, PhD
First Department of Surgery
Yokohama City University School of Medicine
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Early failure of freehand aortic stentless xenograft
valves
To the Editor:
Luciani, Bertolini, and Mazzucco1 report two cases of
supposed early (,12 months) failure with the O’Brien-
Angell stentless porcine xenograft aortic valve (now the
CryoLife-O’Brien model 300 composite aortic stentless
xenograft; CryoLife, Inc., Marietta, Ga.), which they
label as structural failures. The first patient required
reoperation for aortic valve replacement at 8 months. A
large periprosthetic dehiscence of the valve from the
host “for a length of about 1 cm at the level of the
native noncoronary cusp” had occurred. The authors
published a photograph of the explanted valve, which
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they said was originally implanted with a technique
described by O’Brien.2 As the author of this technique
and of the composite stentless valve, I respond and offer
an entirely different interpretation. This is not struc-
tural valve failure. It is incorrect surgical technique of
implantation leading to nonstructural failure of the
device. The method published and recommended is
quite specific and must be used with this valve, because
of the unique single suture line technique and minimal
xenograft aortic wall. It combines a supraannular im-
plantation with this single-layer continuous 3-0 Prolene
suture (Ethicon, Inc., Somerville, N.J.), which must
incorporate virtually all of the xenograft wall. It is
clearly illustrated in the manufacture’s brochure3 and in
the technical article referenced.2 The explant photo-
graph shows that only a small portion of the xenograft
wall has been incorporated in the suture. This incorrect
modification would be totally inadequate to hold the
xenograft in place. The xenograft would be more likely
to tear away, which is precisely the event that occurred.
In addition, this would lead to an unwanted space below
the valve on the ventricular side (Fig. 1). If the surgeon
as well places the valve at anulus level, then unsatifac-
tory hemodynamics would eventuate (Fig. 2). A perfect
implantation must finish with virtually all of the xeno-
graft wall securely pinned against the supraannular
aortic wall above the radically excised valve anulus (Fig. 3).
Luciani, Bertolini, and Mazzucco failed to implant the
valve correctly, and thus a second operation for their
patient was necessary. This is a technical error and not
structural failure of the implant. In a series of 199 patients
treated over 5 years, I have had no structural failures, and
in a larger series of more than 250 patients, Hvass shares
the same experience (U. Hvass, Bichat Hopital, Paris;
personal communication). Therefore 449 patients have
not shown intrinsic structural valve failure over a maxi-
mum of 6 years (minimum 1 month).
For the readers of this letter, three simple technique
diagrams are included to illustrate the correct and incor-
rect methods of implantation (Figs. 1 to 3). The technique
is simple and safe if done correctly, but like many things in
surgery, most advantages of this stentless valve are lost if
the technique is not followed exactly.
The second patient may be somewhat different. Eleven
months after aortic valve implantation, severe stenosis of
the prosthetic stentless xenograft valve occurred, with a
peak pressure gradient of 82 mm Hg. At reoperation the
aortic root and valve leaflets were found to be extensively
covered and distorted by fibrous tissue overgrowth (Fig. 2
from the Luciani article). The scarring was so extensive
that a Nicks root enlargement was necessary before the
insertion of a size 23 Hancock II valve (Hancock Extra-
coporeal Inc., Anaheim, Calif.). The unanswered question
Fig. 1. Suturing only a small rim of the xenograft aortic
wall (as in case 1 of Luciani, Bertolini, and Mazzucco)
gives inadequate fixation of the xenograft to the host and
a space under the unsupported xenograft wall.
Fig. 2. Annular implantation encroaches on or reduces
and lessens the effective valve orifice, compromising he-
modynamics.
Fig. 3. The correct implantation method is depicted.
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is this: Will the same extensive fibrous pannus return?
Pannus has led to reoperation in stented xenografts and
mechanical valves in both the aortic and mitral positions,
yet it is not at all a common phenomenon with the free
subcoronary or root replacement allograft aortic valve. I
believe that the stentless xenograft per se, and particularly
the CryoLife-O’Brien model 300, because of the lack of
Dacron backing, should yield a very low incidence of
pannus ingrowth.
Because of the extent of the fibrosis in patient 2, one
wonders (and Luciani, Bertolini, and Mazzucco do sug-
gest) that there may be in this particular patient “the
involvement of biologic reactions in the host.” Neverthe-
less, Luciani, Bertolini, and Mazzucco do inject a note of
caution that pannus ingrowth has occurred in one patient
of a cohort of 40 patients. In my own series of patients,
closely monitored echocardiographically at 6- to 12-month
intervals over the 5 years, I have seen no evidence of
increasing obstruction. In fact, gradients from the left
ventricle to the aorta drop markedly as left ventricular
regression occurs.
In conclusion, I do not accept structural failure as the
correct interpretation in the first patient described by
Luciani, Bertolini, and Mazzucco. I do accept excessive
fibrous tissue overgrowth of causes unknown that have led
to structural device failure and the need for reoperation in
the second patient.
Mark F. O’Brien, FRACS, FRCS
Department of Cardiac Surgery
The Prince Charles Hospital
Brisbane North Region
Rode Rd.
Chermside
Brisbane 4032, Australia
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Reply to the Editor:
We read with interest the thought-provoking comments
of O’Brien on our report of two cases of structural valve
deterioration observed with the O’Brien-Angell stentless
porcine aortic xenograft (Bravo Cardiovascular model
300, CryoLife, Inc., Atlanta, Ga.).1 Several assertions in
O’Brien’s letter, however, deserve a reply.
Regarding the first case of structural deterioration
caused by rupture of the porcine aortic wall support of the
valve, the explanation offered by O’Brien suggests incor-
rect suprannular positioning of the graft. Accordingly,
incomplete incorporation of all the aortic wall support by
the suture line may have promoted rupture of the support
itself. We believe this to be a possible interpretation for
the failure of the device, although unlikely the correct
one. It is, indeed, unclear how one could demonstrate that
incorrect seating of the xenograft would have occurred
based on the iconography presented in the manuscript.
On the contrary, because of space constraints imposed by
the format of the article, additional photographs of the
explanted device could not be provided, which demon-
strate how the profile of the xenograft was perfectly
preserved. This observation is incompatible with the hy-
pothesis of intraannular positioning of the xenograft,
which, as we have observed on other occasions,2 leads to
profound distortion of the xenograft. The morphologic
alterations of xenografts explanted for nonstructural valve
deterioration persist after removal of the bioprosthesis
and are thus readily apparent from the specimen. More
important, as evident from Fig. 1 in our article, rupture of
the support occurred at the level of the right noncoronary
commissural pillar. At this point, incomplete incorpora-
tion of the aortic wall support by the suture line has no
bearing on the final positioning of the xenograft relative to
the anulus. We therefore believe that the diagram (Fig. 1)
proposed by O’Brien, in which a stitch is shown passing
through the nadir of the excised aortic leaflet, adds little
insight to the interpretation of our case. Furthermore, we
are well aware of O’Brien’s outstanding results and the
reported freedom from structural failure of the xenografts
in his series. O’Brien quotes Hvass’s experience with the
O’ Brien-Angell xenograft to support his own excellent
results. However, Hvass did observe two cases of dehis-
cence of the xenograft resulting from slack suture and
rupture of the suture, respectively. Both cases were la-
beled as technical (nonstructural) failure of the device
because the xenografts were reported to be intact and
“refixing the valves on the anulus would have been
sufficient.”3 It is, however, unclear why both xenografts
were replaced with mechanical prostheses. On the con-
trary, several aspects of those two cases are consistent with
structural failure. Indeed, it is difficult to conceive how
rupture of a suture line in the one case may result in
perivalvular leak 10 months after an “initially perfect
result.”3 In addition, one wonders whether the suture may
be slack in the other case because it has not been correctly
tightened or rather because the support has torn, as
occurred in one of our cases.
The question whether connective tissue ingrowth will
recur in our second patient can only be answered in the
short term. Eighteen months after replacement of the
O’Brien-Angell stentless valve with a Hancock II biopros-
thesis (Hancock Extracoporeal Inc., Anaheim, Calif.),
obstruction of the xenograft has not been shown at
echocardiographic assessment and thus significant pannus
formation can be ruled out.
We are grateful to O’Brien for further supplementing
his technical description on how to implant the O’Brien-
Angell stentless xenografts5 with the three diagrams he
has provided. We believe these technical suggestions to be
of premiere importance in avoiding nonstructural failure
of the xenograft resulting from inadequate suprannular
positioning of the valve, which has occurred in our expe-
rience2 as well as in Dr. Hvass’s.3, 4 We remain convinced,
however, that structural failure of this valve, certainly
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